Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-22-036617
Filing Date
2022-11-03
Accepted
2022-11-03 16:18:28
Documents
57
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q stsa-10q_20220930.htm   iXBRL 10-Q 2502351
2 EX-31.1 stsa-ex311_9.htm EX-31.1 21717
3 EX-31.2 stsa-ex312_7.htm EX-31.2 21477
4 EX-32.1 stsa-ex321_6.htm EX-32.1 9911
5 EX-32.2 stsa-ex322_8.htm EX-32.2 9835
  Complete submission text file 0001564590-22-036617.txt   7326206

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA stsa-20220930.xsd EX-101.SCH 38481
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE stsa-20220930_cal.xml EX-101.CAL 40070
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE stsa-20220930_def.xml EX-101.DEF 90715
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE stsa-20220930_lab.xml EX-101.LAB 315012
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stsa-20220930_pre.xml EX-101.PRE 222483
51 EXTRACTED XBRL INSTANCE DOCUMENT stsa-10q_20220930_htm.xml XML 1282015
Mailing Address 400 OYSTER POINT BOULEVARD SUITE 221 SOUTH SAN FRANCISCO CA 64080
Business Address 400 OYSTER POINT BOULEVARD SUITE 221 SOUTH SAN FRANCISCO CA 64080 415-505-0809
Satsuma Pharmaceuticals, Inc. (Filer) CIK: 0001692830 (see all company filings)

EIN.: 813039831 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39041 | Film No.: 221358300
SIC: 2834 Pharmaceutical Preparations